Dr Bill Deagle MD, Nutrimedical Report
Ebola has appeared in three African nations in 2014 with exponential growth, 71% case fatality, and grossly incompetent response on a local and international level. The resent sending of 160,000 hazmat separate air biohazard suits via the US State Dept to Africa confirms 2012 Canadian research, that Ebola is airborne. Since 1976, Ebola was of short incubation period approximately 4 to 7 days, before rapid onset of terminal DIC disseminated intravascular coagulopathy. The lab where Ebola research in Sierra Leone has been funded by Bill and Melinda Gates and George Soros, under the direction of the CDC of the USA and UN / WHO. The 2010 USA patent by the CDC on Ebola indicates they had interest in genetic and pathogenic modification of the virus. Its recent rise and spread lend support to the thesis that it is a bioweapon designed to firstly depopulate Africa, and secondly to force travel controls, medical martial law and by 2006 international treaties that pass all military under the UN and all health controls under the WHO.
Ebola mimics early malarial symptoms in Africa, where citizens are prone to go to the local pharmacy or natural doctors for malarial treatment. The population is very suspicious of outside health providers and tend to run from any suggestion of Ebola as a possible diagnosis. Normal self-quarantine is totally useless in Africa, and 21, 30 day time for quarantine is inadequate. It should be sixty days minimum, with monitoring of each person in a separate biohazard room, with no day privileges to leave the facility. Anyone under surveillance must have daily medical checks, viral swabs, blood titers and testing to indicate viral load, and any indication of progression to overt disease which may follow false negative testing results.
Ebola has a reservoir in fruit bats, monkeys and cattle in Africa. It can also infect domestic animals cats, and dogs, as well as carrion birds such as crows, seagulls and eagles.
1) Cancel all travel Visas to the USA and Western nations from these target countries and any new countries identified to have Ebola outbreaks.
2) FAA to place a Hazmat team on all aircraft to isolate anyone with symptoms presumptive of Ebola with a hazmat tent and isolation of one restroom, at the back of the aircraft. NIOSH N95 masks and biohazard TyVek Suits for suspected tracellers and hazmat team with separate air systems with filters.
3) HEPA filters with chain of custody to CDC Certified viral and pathogen labs for every international flight, with contract call list of travellers and followup for minimum three weeks from suspected contact on an identified flight of concern.
4) Hazmat teams and ground transfer vehicles to quarantine facilities at every USA or Western international airport.
PPE Level 3 and 4 Equipment with separate air systems and degowning airlock 1.3 Atmospheres Ozonate Ionic Silver Citrate aeosol environment for viral suppression wtih degowning techs in airlock to accomplish task without contamination of health professionals.
5) Ozone and Ionic Silver clearance of all aircraft and all luggage with UV curtains and Wood's light 'grime light' clearance of seats, lavatories, and all passenger contact points.
6) Development of rapid DNA amplification technologies for rapid identification of Ebola or any other suspect pathogen, for airline, hospital, EMT AND Hazmat staff. see BioFire and BioPhoton device articles at end of report, now available for Ebola and other Pandemic Viral Detection in 1 hour.
7) Personal immune Hygiene - Send to involved population, EMT / Emergency, BSL2 to 4 Hospital Personnel, High Risk Individuals and Public if pandemic status is breached by criteria of international spread and ratio of infectivity.
ICU therapy started early with viral detection, including electrolyte, cytokine suppression with oral / feeding tube Power C PLUS, I.V. Vitamin C and enzymatic AllerGone / AllerBlock, NutriTRALA, Cell Detox Glutatthione, ReGenerex and receptor binding domain Vitamin D3 and D2, with constant moniitoring breath and urine markers of free radicals and blood electrolytes with mobile fingerprick monitors and rapid lab testing devices.
Antipathogenics, Immune Boosters, Viral Defense / Flu Defense Kits - Nutriodine, AllicinMED, Silver 100, ImmunoMAX / Nutrimmune. NutriDefense, Power C PLUS / Full Vitamin K2, MyCell D3, MyCO D2 Oncomycin available at www.NutriMedical.com
8 ) Avoid contact with body fluids, stool, vomitus, coughing in vicinity, sweat and clothing or personal furniture e.g. bedding, chairs, coaches, and footwear.
9) Self quarantine at home for the duration of an outbreak plus eight weeks in your rea of the county, e.g. prepper needs water, food, personal protection.
10) Refuse all vaccines, drugs, and government detention camps
11) Under development -
ZMapp tobacco genetically modified sera tags pathogenic Ebola virus, and production should be dramatically increased. Similar H1N1, H5N1, H57N9, SARS Beta 2 Corona Virus should be explored.
Also other monoclonal antibodies may be helpful but limited supply and viral genetic evolution and drift could make less useful
Avoid Vaccine with Adenovirus and two genes to make your cells produce Ebola antigenic immune stimulus
12) Plan with Hamm Radio, Local Sherrif's offices, civilian defense teams to control movement of public, gas, food, services, mail etc. to prevent further spread of the pathogen.
13) Quarantine only if positive BioFire or BioPhoton Tests / PCR with or without symtoms - Personal and Military Quanantine to reduce contact from possible infective cases and people shedding virus before symptomatic.
From Ebola countries and if pandemic status is reached all international flights should be cleared before flights, boats, or immigrationis permitted, which should only take one hour.
14) To prevent endemic viral breakouts in bushmeat animals e.g. monkeys and fruit bats and agricultural animals and pets a national endemic team project to identify and elminate repositories with antipathogenics, scalar antiviral technologies and individual and herd culling. E.G. Liberian, Sierra Leone, Guinea international veterinarian teams - multiyear project.
PROTOTYPE USES LED LIGHTS TO DETECT EBOLA
Digital Sensing and Sizing of Vesicular Stomatitis Virus Pseudotypes in Complex Media: A Model for Ebola and Marburg Detectionhttp://pubs.acs.org/doi/abs/10.1021/nn501312q
ACS ActiveView PDFHi-Res Print, Annotate, Reference QuickViewPDF [2648 KB]PDF w/ Links[555 KB]Full Text HTMLAbstractSupporting Info ->FiguresReference QuickView Add to ACS ChemWorx
George G. Daaboul (1), Carlos A. Lopez (1), Jyothsna Chinnala (1), Bennett B. Goldberg (1)(2)(3), John H. Connor (4)(5), and M. Selim Unlu (1)(2)(3)(6)
(1) Electrical & Computer Engineering Department, Boston University, Boston, Massachusetts 02215, United States
(2) Biomedical Engineering Department, Boston University, Boston, Massachusetts 02215, United States
(3) Physics Department, Boston University, Boston, Massachusetts 02215, United States
(4) Department of Microbiology and National Emerging and Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States
(5) Boston University Photonics Center, Boston University, Boston, Massachusetts 02215, United States
ACS Nano, 2014, 8 (6), pp 6047-6055
Publication Date (Web): May 19, 2014
Copyright (c) 2014 American Chemical Society
(6)Address correspondence to email@example.com
Rapid, sensitive, and direct label-free capture and characterization of nanoparticles from complex media such as blood or serum will broadly impact medicine and the life sciences. We demonstrate identification of virus particles in complex samples for replication-competent wild-type vesicular stomatitis virus (VSV), defective VSV, and Ebola- and Marburg-pseudotyped VSV with high sensitivity and specificity. Size discrimination of the imaged nanoparticles (virions) allows differentiation between modified viruses having different genome lengths and facilitates a reduction in the counting of nonspecifically bound particles to achieve a limit-of-detection (LOD) of 5 X 103 pfu/mL for the Ebola and Marburg VSV pseudotypes. We demonstrate the simultaneous detection of multiple viruses in a single sample (composed of serum or whole blood) for screening applications and uncompromised detection capabilities in samples contaminated with high levels of bacteria. By employing affinity-based capture, size discrimination, and a "digital" detection scheme to count single virus particles, we show that a robust and sensitive virus/nanoparticle sensing assay can be established for targets in complex samples. The nanoparticle microscopy system is termed the Single Particle Interferometric Reflectance Imaging Sensor (SP-IRIS) and is capable of high-throughput and rapid sizing of large numbers of biological nanoparticles on an antibody microarray for research and diagnostic applications.
Keywords: single virus; viral hemorrhagic fevers; label free; biosensor
View: ACS ActiveView PDF | PDF | PDF w/ Links | Full Text HTML
BOSTON UNIVERSITY - EBOLA BIOPHOTON DETECTION KIT IN AN HOURhttp://www.futurity.org/ebola-sensor-viruses-791432/
Posted by Mark Dwortzan-Boston U on October 27, 2014
In a worst-case scenario, 1.4 million people in Liberia and Sierra Leona could be infected with Ebola by late January, according to the US Centers for Disease Control and Prevention.
The CDC warns that those countries could now have 21,000 cases of the virus, which kills 70 percent of people infected.
One of the big problems hindering the containment of Ebola is the cost and difficulty of diagnosing the disease when a patient is first seen. Conventional fluorescent label-based virus detection methods require expensive lab equipment, significant sample preparation, transport and processing times, and extensive training to use.
A rapid, label-free photonic device that can provide affordable, simple, and accurate on-site detection could be a potential solution. The device could be used to diagnose Ebola and other hemorrhagic fever diseases in resource-limited countries.
DIAGNOSIS IN AN HOUR
A team, led by Selim Unlu, a professor of biomedical engineering, electrical and computer engineering, and materials science and engineering at Boston University, in collaboration with physics professor Bennett Goldberg, showed the ability to pinpoint and size single H1N1 virus particles.
Researchers reported the first demonstrated of the concept in Nano Letters in 2010.
To make tiny graphene ribbons, simply add water
University of Toronto
No-fuss device delivers entangled photons
'Spider' molecules behave like nanorobots
California Institute of Technology
'Spider' molecules behave like nanorobots
Now, after four years of refining the instrumentation with collaborators including John Connor, a School of Medicine associate professor of microbiology, the team has demonstrated the simultaneous detection of multiple viruses in blood serum samples-including viruses genetically modified to mimic the behavior of Ebola and the Marburg virus.
The device identifies individual viruses based on size variations resulting from distinct genome lengths and other factors. Funded by the National Institutes of Health, the research appears in the May 2014 ACS Nano.
"Others have developed different label-free systems, but none have been nearly as successful in detecting nanoscale viral particles in complex media," says Unlu, referring to typical biological samples that may have a mix of viruses, bacteria, and proteins.
"Leveraging expertise in optical biosensors and hemorrhagic fever diseases, our collaborative research effort has produced a highly sensitive device with the potential to perform rapid diagnostics in clinical settings."
Whereas conventional methods can require up to an hour for sample preparation and two hours or more for processing, the current prototype requires little to no sample preparation time and delivers answers in about an hour.
"By minimizing sample preparation and handling, our system can reduce potential exposure to health care workers," says Connor, a researcher at Boston University's National Emerging Infectious Diseases Laboratories (NEIDL).
"And by looking for multiple viruses at the same time, patients can be diagnosed much more effectively."
HOW IT WORKS
The shoebox-sized prototype diagnostic device, known as the single particle interferometric reflectance imaging sensor (SP-IRIS), detects pathogens by shining light from multicolor LED sources on viral nanoparticles bound to the sensor surface by a coating of virus-specific antibodies.
Interference of light reflected from the surface is modified by the presence of the particles, producing a distinct signal that reveals the size and shape of each particle. The sensor surface is very large and can capture the telltale responses of up to a million nanoparticles.
In collaboration with BD Technologies and NexGen Arrays, a start-up based at the Photonics Center and run by longtime SP-IRIS developers David Freedman and postdoctoral fellow George Daaboul, the research team is now working on making SP-IRIS more robust, field-ready, and fast-ideally delivering answers within 30 minutes-through further technology development and preclinical trials.
SP-IRIS devices are now being tested in several labs, including a Biosafety Level-4 (BSL-4) lab at the University of Texas Medical Branch, which is equipped to work with hemorrhagic viruses.
Other tests will be conducted at the university's NEIDL once the facility is approved for BSL-4 research. Based on the team's current rate of progress, a field-ready instrument could be ready to enter the medical marketplace in five years.http://www.biofiredefense.com/
At BioFire Defense we deliver a fully integrated suite of biological agent identification products, including the FilmArray system, and life science systems to the biodefense and first responder community. Our products and services speed up medical results, help people stay healthy and make communities more secure. Simply put, we make the world a safer and healthier place.
BioFire Defense Receives EUA of FilmArray Ebola Test (10/25/2014)
BioFire Defense NGDS Contract Award (3/18/14)
BioFire Diagnostics Inc. announces intent to merge with bioMerieux (9/3/2013)
BioFire Initiates Clinical Study for the FilmArray(r) Gastrointestinal Panel (7/30/2013)
BioFire Receives FDA Clearance for the FilmArray(r) Blood Culture Identification Panel (6/25/2013)
FilmArray(tm) BioThreat Panel
1 Test. 16 BioThreat Pathogens/26 Targets. All in about an hour.
Multi-Use: Used for BioThreat Detection and Pandemic BioSurveillance.
Easy-to-Use: Automated protocol requires limited hands-on time and training.
More BioThreat Targets: Test for Ebola and 15 other pathogens in one run.http://www.infowars.com/doctor-u-s-army-rejected-successful-ebola-drug-2-weeks-before-outbreak/
DOCTOR: U.S. ARMY REJECTED SUCCESSFUL EBOLA DRUG 2 WEEKS BEFORE OUTBREAK
Exclusive: Former flight surgeon had been working with Ft. Detrick to develop treatment
Doctor: U.S. Army Rejected Successful Ebola Drug 2 Weeks Before Outbreak
Image Credits: CDC Global
by PAUL JOSEPH WATSON | OCTOBER 16, 2014
Share on Facebook0Tweet about this on Twitter633Share on Google+0Email this to someonePrint this page
A doctor claims that he developed a successful drug to combat Ebola with the U.S. Army at Ft. Detrick Maryland but that the research was inexplicably shut down two weeks before the first outbreak of the virus in West Africa.
Richard C. Davis, M.D., a former flight surgeon with the U.S. Navy, told Infowars that he was leading a project to develop a drug called RC-2Beta, which according to Davis works, "at the core of our cells to enhance mitochondrial efficiency and promote gene signaling to stimulate cellular self-repair and pathogen destruction."
In the fall of 2013, Davis' company began collaborating with the US Army at their Level 4 bioweapons facility at Ft. Detrick, Maryland to develop the drug, with astounding success.
According to Davis, the drug "Killed four of the world's deadliest viruses in a dose-dependent fashion. The Army also noted that uninfected cells in the same cultures were untouched by the drug (i.e., it was non-toxic)."
"Everyone was very excited about these results since there has never been a broad-spectrum anti-viral drug that killed so many different viruses without affecting normal (uninfected) cells in this way," writes Davis.
However, after the Army initially indicated to Davis and his team that they were ready to move ahead quickly with further testing, communication completely ceased.
Army research data shows effectiveness of RC-2Beta in fighting the Ebola virus.
"Our once close communications and cordial relationship with the Ft. Detrick team went totally and inexplicably silent. Our phone calls went unanswered and emails unreturned," writes Davis, adding he was "stunned" when the first reports of Ebola emerged in Africa just two weeks later.
The doctor also desperately contacted mainstream media outlets in an effort to get the story out, including CNN, ABC, MSNBC, CBS, the New York Times, the Washington Post, the LA Times and others. After making initial contact and agreeing to provide documents, Davis was subsequently stonewalled and every outlet dropped the story.
Davis then turned to Florida Congressman David Jolly in an effort to reopen lines of communication with Ft. Detrick, a process that is ongoing.
While health authorities and the media aggressively promoted ZMapp and other less successful drugs and vaccines to fight Ebola, Davis set about anxiously contacting the World Health Organization, which in June announced that experimental treatments for Ebola would be fast tracked.
"Out of concern and frustration, I made it my personal priority to obtain the two necessary documents (Humanitarian Use Exemption and Export Certificate) needed to ship our drug to the medical teams working desperately in Africa," writes Davis. "So I began calling, and writing and faxing everyone who might be able to help. Since May, I have reached out over 200 times to every head of every organization in the world involved with this crisis. This includes the World Health Organization, the Centers for Disease Control, the various teams at the FDA, the National Institutes of Health, DARPA, multiple private relief and aid organizations (like Doctors Without Borders), and dozens just like them. The response was always the same... Silence..."
The doctor also slammed the Obama administration's response to the Ebola outbreak.
"The response of the American government has been patently absurd," writes Davis. "Every protocol that has been put in place to prevent the spread of the disease has been ignored. Our borders remain open, infected patients are being brought into our hospitals, and no truly effective countermeasures have been erected to stem the tide of infectious risk."
Davis' conclusion on the government's handling of the Ebola crisis and the fact that a potentially successful cure for the virus was shut down by Ft. Detrick immediately before the outbreak in West Africa left him to draw a sobering conclusion.
"I am left to conclude that America's leadership is either guilty of gross misconduct, dereliction of duty, criminal negligence or worse - treason," writes Davis, warning that the "crisis will undoubtedly spiral out of control" if the advice of incompetent public health authorities, the government and the media continues to be followed unquestionably.
Davis boasts an impressive Curriculum Vitae, having authored over 400 patents and trademarks while also being awarded commendations from the Chief of Naval Operations.
"The inescapable conclusions of negligence or corruption or both cannot be simply swept aside for the sake of political correctness when the lives of every one of us are at stake," writes Davis, adding, "Ebola is real. It is here, now. There is no more time to waste."
Facebook @ https://www.facebook.com/paul.j.watson.71
FOLLOW Paul Joseph Watson @ https://twitter.com/PrisonPlanet
Paul Joseph Watson is the editor at large of Infowars.com and Prison Planet.com.